Does your company have a therapeutic candidate (small molecule, monoclonal antibody, combination product, or other) for the treatment of a type of cancer? Does your therapeutic candidate have multiple indications for multiple types of cancers (e.g., drugs targeting reactive oxygen species [ROS] or cell surface receptors [GPCRs, EGFR]; protein inhibitors [Hsp90, ATR kinase]; epigenetic enzymes [LSD1]; or combination therapies [erlotinib ...
Continue Reading →
9
DEC
DEC
0